TNKS and neoplasm: Among the identified tankyrase inhibitors, XAV939 (Huang et al. 2009) has been the most widely studied and exhibits potent efficacy and antitumor activity in in vitro and in vivo preclinical tumor models (Luo et al. 2022, Neiheisel et al. 2022).